Abstract
INTRODUCTION
In Africa, approximately 60 million individuals are chronically infected with hepatitis B virus (HBV). In formed by Asian and European data, international recommendations were developed to guide policyma kers and implementers on diagnosis and treatment of chronic HBV in resourceconstrained settings [13] . In settings with hepatitis B surface antigen (HBsAg) positivity > 2%, both general population testing and targeted testing of populations with higher disease burden are recommended; however, limited real world data from Africa are available. In addition, understand ing the proportion of patients diagnosed with chronic HBV infection who would benefit from antiviral therapy in African settings is not wellestablished.
Several recent studies have informed scaleup of HBV treatment in Africa. In Zambia, integration of HBsAg testing into a populationbased HIV survey revealed 5.6% of adults and 1.3% of children to be HBsAgpositive (Zambian Ministry of Health, 2016 #599). A research program in Gambia demonstrated the feasibility of community screening, linkage to a comprehensive liver evaluation, and initiation of antiviral treatment [4] . Among potential key populations (sex workers and men who have sex with men) in West Africa and adults in Ethiopia, approximately 10% met criteria for antiviral therapy but another 50% had markers requiring longitudinal follow up [5] . Building on these and other studies, we established an observational cohort study at a referral hospital in Lusaka, Zambia. We described where Zambians are currently being tested for HBV and among those with no prior HBV treatment, we categorized patients into the classical stages of HBV using biochemical, virological, and noninvasive markers of liver fibrosis. We also estimated patient eligibility for antivirals according to international guidelines. Among patients already taking antiviral therapy, we described medication side effects, adherence, and viral suppression.
MATERIALS AND METHODS

Study setting and participant recruitment
In Zambia, 5.6% of adults and 1.3% of children are estimated to be HBsAgpositive [6] , and HBV genotypes A1 and E are present at nearly equal proportions [7] . HBsAg testing is part of the evaluation of signs or sym ptoms of liver disease, and routine testing in Zambia occurs at several settings, including at the blood bank, during community screening events (sometimes inte grated with HIV testing), and as part of medical check ups to obtain a driving license, enroll in college, start a new job, etc. Following an HBsAgpositive diagnosis, some Lusaka area residents are referred to Univers ity Teaching Hospital (UTH), a public tertiary care and academic medical facility with > 1000 inpatient beds located in Zambia's capital of Lusaka. At UTH, the Department of Internal Medicine hosts a weekly liver clinic that is staffed by three gastroenterologytrained physicians and provides specialty care for patients with acute and chronic liver disease, hepatic lesions, and portal hypertension.
From August 23, 2016 to August 18, 2017, after obtaining the required ethical and government appro vals, 160 HBsAgpositive HIVnegative adults (18+ years old) were enrolled in a cohort study at the UTH liver clinic. HIVHBV coinfected individuals identified during recruitment for the cohort were referred for immediate linkage to and initiation of antiretroviral therapy accord ing to national guidelines [8] . We excluded patients from provinces outside of Lusaka to reduce losses to follow up. Participants provided written informed consent to be followed for up to five years.
Study measures
Although specific HBV management guidelines are li mited in Zambia, international standards of care are followed. At cohort enrollment, we performed a comple te physical examination, including vital signs and body mass index (BMI), and extracted data from participants' medical records related to HBV testing, treatment, laboratory and imaging tests, and liver biopsy results when available. A standardized questionnaire was used to document sociodemographic information, comorbid conditions, and to screen for and quantify alcohol con sumption using the alcohol use disorders identification testconsumption (AUDITC) [9] . Among those already on antiviral drugs for HBV at cohort enrollment, we asses sed current or prior drug side effects and selfreported medication adherence in the past 7 d.
Blood was collected for measurement of serum transaminases, hemoglobin, platelet count, hepatitis B eantigen (HBeAg), and HBV viral load, which was determined using either the Roche COBAS AmpliPrep/ COBAS Taqman platform (Pleasanton, CA, United States) or an inhouse real time PCR assay [10] . We measured liver stiffness noninvasively with the Aspartate Amino transferase (AST)toplatelet ratio index [11] and with transient elastography (TE; Fibroscan 402, Echosens, Paris, France). TE was performed by a nurse or physician trained according to manufacturer guidelines and with experience performing > 500 tests. Testing for hepatitis C and hepatitis delta was not routinely performed as they are rare in Zambia [12, 13] .
Statistical analysis
Among treatmentnaïve patients (i.e., no prior history of antiviral therapy), we described demographics and clinical features stratified by type of HBsAg test (clinical or routine). We compared baseline characteristics mea sured on categorical scale between clinical and routine diagnosis using Fisher's exact test. For comparison of median between the two groups, we used Wilcoxon rank sum test. Obesity was BMI > 30 and unhealthy alcohol consumption was AUDITC of 4+ for men and 3+ for women. Among antiviral naïve participants, we described HBV viral loads, HBeAg, serum transaminase levels, and the proportion of patients with cirrhosis. In our primary analysis, we defined elevated ALT as > 30 U/L for men and > 20 U/L for women per WHO recommendations [3] . We defined persistently elevated ALT as any degree of baseline ALT elevation plus an elevated measurement at > 60 d prior to baseline. Significant fibrosis (equivalent to Metavir fibrosis stages F2-4) was defined as liver stiffness measurement (LSM) of 7.99.5 kPa based on a validation study in West Africa [14] . We defined cirrhosis as having at least one of the following: APRI > 2.0 [11] , LSM > 9.5 kPa [14] , or decompensated cirrhosis on physical examination defined by the presence of ascites.
Using ALT, HBeAg, and HBV DNA at enrollment, we categorized treatmentnaïve participants into one of the classical stages of chronic HBV infection. Immune tolerant stage was defined as HBeAg-positivity, normal ALT, and HBV DNA > 20000 IU/mL. Immune active HBV was defined as either HBeAgpositive, elevated ALT, and HBV DNA > 20000 IU/mL or HBeAgnegative/ unknown with elevated ALT and HBV DNA > 2000 IU/ mL. Inactive carriers were those with HBeAgnegative/ unknown status, normal ALT, and HBV DNA < 2000 IU/mL. Participants not categorized into one of these three stages were considered to have an indeterminate phenotype [15] . We repeated this categorization using the "conventional" ALT upper limit of normal (i.e., 40 IU/ mL). We compared unhealthy alcohol use and obesity between indeterminate patients with HBV DNA < 2000 and ALT elevation and inactive carriers using a χ 2 test.
We determined eligibility for antiviral therapy if pa tients met one of these criteria based on WHO guide lines: (1) decompensated cirrhosis; (2) APRI > 2.0; or (3) HBV DNA > 20000 IU/mL with ALT elevation and age > 30 years. We also assessed treatment eligibi lity per European Association for Study of the Liver (EASL) criteria [2] as follows: (1) We compared treatment eligibility, per WHO criteria, between those who were diagnosed with a clinically driven vs routine HBsAg test using logistic regression and adjusting for age and sex. Among treatment experienced patients, we descri bed antiviral therapies received, time on therapy, history of side effects, and selfreported adherence. We reported the proportion with viral suppression (VS) defined as HBV DNA < 20 IU/mL among those on therapy for 2+ years. Analyses were performed using Stata version 14 (Statacorp, College Station, TX, United States). The statistical review of the study was performed by a biomedical statistician. The cohort was approved by the ethics committees at University of Zambia (Lusaka, Zambia) and University of Alabama at Birmingham (Birmingham, AL, United States).
RESULTS
Median age was 33 years (IqR, 2642), 115 (71.9%) were men, and the majority (n = 84, 52.6%) were recently diagnosed with HBV. The majority were dia gnosed at routine HBsAg testing during community/ routine medical checkups (n = 58; 36.2%) or at the blood bank, while 49 (30.6%) were tested due to signs/ symptoms of possible liver disease (i.e., clinical test). Current alcohol consumption at "unhealthy levels" was reported by 19 According to WHO guidelines, 13 (10.8%) treatment naïve patients were deemed to be eligible for antiviral therapy at cohort enrollment (Table 2) . Of these, five became eligible for decompensated cirrhosis, two for APRI > 2.0, and six for HBV DNA > 20000 IU/mL with ALT elevation and age > 30 years. Among patients diagnosed during a routine HBsAgtest, 4 (4.6%) met WHO treatment criteria vs 9 (29.0%) of those with clinicallydriven HBsAg testing. After adjusting for age and sex, there was 8 times higher odds of treatment eligibility for clinically vs routinelydiagnosed patients (adjusted odds ratio, 8.33; 95%CI: 2.2629.41). By EASL guidelines, 21 (17.5%) were eligible for antiviral therapy.
Among 40 treatmentexperienced patients, 31 were currently taking antivirals at enrollment with the majority (85%) on fixed dose combination TDF plus 3TC. Median time on therapy was 12.2 mo (IqR, 5.024.3). Al though complete medical records were not available for all patients, many treatmentexperienced patients had a history of significant fibrosis/cirrhosis at time of initiation. A minority of patients (n = 6; 20.0%) reported at least one side effect in the past/present attributed to antivirals, including nausea, diarrhea, skin rash, itchiness, dizziness, drowsiness, or mild headache. Among those on therapy at enrollment, 17 of 29 (58.6%) had complete HBV DNA suppression including 5 of 9 with 2+ years on treatment. Among the four individu als with HBV DNA nonsuppression during longterm therapy, all HBV DNA levels were < 2000 IU/mL. Among those currently on antivirals, median adherence was 100% but 12.5% reported missing at least one dose in the prior 7 d.
DISCUSSION
Approximately 1 in 10 Zambian adults with HBV mo noinfection met international guidelines for immediate antiviral therapy, and an additional half had either elevated ALT or HBV DNA > 2000 IU/mL, suggesting the need for further followup. Participants diagnosed on suspicion of having HBV were more likely to require therapy compared to those HBsAg tested at routine settings. Antiviral therapy was well tolerated among treatmentexperienced participants; however, a subset had HBV DNA nonsuppression. These data are some of the first data on modern HBV treatment in Southern Africa and provide insights around the scaleup of testing for and treatment of chronic HBV infection in Africa.
While many chronic HBV patients in Zambia had elevated ALT, relatively few qualified for immediate antiviral therapy when we applied international guide lines. By WHO guidelines around 10% of treatment naïve patients met criteria and by EASL criteria this was closer to 20%. These results are supported by Gambian data where 4.4% in the community and 9.7% of blood donors met EASL criteria [4] . In a smaller study of female sex workers, men who have sex with men, and inmates in West Africa, 10.0% were also treatmenteligible based on modified WHO criteria [5] . Taken together these research data suggest that the WHO criteria are very stringent and might be missing some patients who could benefit from antiviral therapy. Although not surprising, we also observed that symptomatic patients were more likely to meet treatment eligibility compared to those tested in routine settings. Further data are needed to understand the most efficient way to identify HBV patients who would benefit from antiviral therapy in Zambia and similar settings.
Based on their enrollment values, 35% of our par ticipants were classified as inactive carriers and half had indeterminate HBV phenotypes. Identification of inactive carriers, a group at low risk to progress to cirrhosis or develop HCC [16] , is useful in programmatic settings in Africa. For example, at an HBV treatment program in Ethiopia, inactive carriers (also representing around one third of patients) will be discharged from care after one year in order to focus resources on those more likely to benefit from therapy [17] . Unfortunately, our cohort and others have reported that a substantial percentage of patients cannot be initially categorized as needing or not needing therapy (i.e., indeterminate phenotype). In Senegal, 53% did not qualify for antivirals but had either significant fibrosis, raised ALT, or significant HBV DNA levels [5] . In the HBV Research Network (HBRN) in North America, 38% had indeterminate phenotype at base line and will be followed longitudinally [15] . Similar to the HBRN, most patients with indeterminate disease stage September 27, 2018|Volume 10|Issue 9|
in Zambia had elevated ALT with HBV DNA < 20000 IU/mL, suggesting nonHBV reasons for ALT elevation.
Although we did not find that they were correlated with having indeterminate stage, fatty liver and hazardous alcohol use are potential causes of elevated ALT in HBV patients. Longitudinal followup to ascertain whether patients of indeterminate stage develop treatment indications or become inactive carriers is needed in Africa to guide HBV policy [5] . Our data from treatmentexperienced Zambians with chronic HBV monoinfection support the feasibility of longitudinal treatment with antiviral therapy in African settings. TDF + XTC was the most common regimen as this fixeddose combination drug is found in large supply in Zambia to treat and prevent HIV/AIDS. We documented HBV DNA nonsuppression among the small group on longterm therapy which requires further followup. We presumed suboptimal adherence as the mechanism, although most of our patients selfrepor ted good adherence in the prior week. Our data are con trasted by the PROLIFICA study in the Gambia where 43 of 47 (91.5%) tenofovirtreated HBV monoinfected individuals achieved viral suppression at one year [4] . Lower HBV DNA suppression in our cohort may reflect differences in study design (clinical trial vs hospital cohort) or could reflect HBV genotypic differences as Gambia has predominantly HBV genotype E and Zambia has both E and A1, a genotype that rapidly developed lamivudineresistance in Malawi [18] . This study has several limitations. Most importantly, our cohort is based at one site in Zambia and may not represent other HBVinfected populations. Our cohort is hospitalbased and enriched for sicker patients eviden ced by the fact that participants referred from clinical settings were eight times more likely to be treatment eligible compared to other HBsAgpositives. To offset this, we also characterized a subset of participants diagnosed at routine settings such as the blood bank and a populationbased survey. Finally, we had incomplete laboratory and clinical data that led to incomplete eva luation of some patients and inflated our estimate of the proportion with indeterminate HBV. We believe the missing data occurred at random and would not have introduced bias into the distribution of HBV stages.
In summary, an HBV monoinfection cohort was es tablished at a referral hospital in Zambia to begin to answer a number of clinical and operational questions around HBV treatment in Africa. We observed that 1 in 10 patients who underwent comprehensive assessment met the WHO criteria for therapy, although the number was higher among those with signs/symptoms and lower among those diagnosed during routine HBsAg testing. These data support scaleup of HBV testing and treatment in Africa, but further operational and clinical research is needed to define the most effective and efficient way to reduce HBV-related mortality and morbidity.
ARTICLE HIGHLIGHTS
Research background
Africa has 60 million individuals living with chronic hepatitis B virus (HBV) infection yet limited data to inform how to identify, link to care, and treat them to reduce the burden of cirrhosis and liver cancer.
Research motivation
Not all HBV patients need antivirals. Estimates on how many do will guide policy implementation. Also, few data are available on patient adherence, retention, and viral suppression with current antiviral drugs.
Research objectives
Our objective was to perform a comprehensive clinical assessment on chronic HBV-infected adults in Zambia and apply international criteria to learn what percentage may need antiviral drugs. In those already on antivirals, we measured the viral control.
Research methods
At a university hospital in Zambia, a cross-sectional assessment of adults (18+ years old) who were hepatitis B surface antigen positive and HIV negative was undertaken during 2016-2017. We used tests available in upper-income settings such as HBV DNA testing and transient elastography to assess HBV in these patients.
Research results
One hundred and sixty enrolled in the study, including 120 who were recently diagnosed with HBV and 40 already on antiviral drugs. The average age was 33, and 72% were men. We found that 1 in 10 met the World Health Organization guidelines to start antivirals; however, nearly 1 in 2 had at least one finding that would need clinical follow-up. Patients diagnosed because of signs or symptoms of HBV were slightly more likely to need antivirals compared to those diagnosed via routine testing (such as at the blood bank). Among those September 27, 2018|Volume 10|Issue 9|
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